Nitrogen Bonded Directly To Ring Carbon Of The 1,3-diazine Ring Of The Quinazoline Ring System Patents (Class 514/266.4)
  • Publication number: 20100048561
    Abstract: The invention provides quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.
    Type: Application
    Filed: April 5, 2007
    Publication date: February 25, 2010
    Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventors: Savithri Ramurthy, Xiaodong Lin, Sharadha Subramanian, Alice C. Rico, Xiaojing M. Wang, Rama Jain, Jeremy M. Murray, Steven E. Basham, Robert L. Warne, Wei Shu, Yasheen Zhou, Jeffrey Dove, Mina Aikawa, Payman Amiri, Weibo Wang, Johanna M. Jansen, Allan S. Wagman, Keith B. Pfister, Simon Ng
  • Publication number: 20100048503
    Abstract: Disclosed are a pharmaceutical composition having excellent antitumor activity, and a method for treating a cancer. Specifically, excellent antitumor activity is achieved when 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or an analogous compound thereof, a pharmacologically acceptable salt thereof or a solvate thereof is used in combination with gemcitabine or erlotinib, a pharmacologically acceptable salt thereof or a solvate of any of them.
    Type: Application
    Filed: January 18, 2008
    Publication date: February 25, 2010
    Applicant: Eisai R & D Management Co., Ltd.
    Inventor: Yuji Yamamoto
  • Publication number: 20100028338
    Abstract: A combination therapy for treating patients suffering from proliferative diseases or diseases associated with persistent angiogenesis is disclosed. The patient is treated with a camptothecin derivative and one or more chemotherapeutic agents selected from a microtubule active agent; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a topoisomerase II inhibitor; a VEGF inhibitor; a tyrosine kinase inhibitor; an EGFR kinase inhibitor; an mTOR kinase inhibitor; an insulin-like growth factor I inhibitor; a Raf kinase inhibitor; a monoclonal antibody; a proteasome inhibitor; a HDAC inhibitor; and ionizing radiation.
    Type: Application
    Filed: December 13, 2005
    Publication date: February 4, 2010
    Inventors: Sara Zaknoen, Margaret Ma Woo, Richard William Versace, Claudio Pisano, Loredana Vesci
  • Publication number: 20100022505
    Abstract: The present invention relates to bicyclic heterocycles of general formula wherein Ra, Rb and Rc are defined as in claim 1, their tautomers, their stereoisomers, their mixtures and their salts, in particular their physiologically acceptable salts with inorganic or organic acids and bases, which have valuable pharmacological properties, in particular an inhibitory action on the signal transduction mediated by tyrosine kinases, their use for the treatment of illnesses, in particular of tumoral diseases and of benign prostatic hyperplasia (BPH), of diseases of the lung and of the airways, and the preparation thereof.
    Type: Application
    Filed: January 30, 2008
    Publication date: January 28, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Frank Himmelsbach, Birgil Jung, Ralf Lotz, Markus Ostermeier
  • Publication number: 20100022566
    Abstract: The present invention relates to novel quinazoline derivatives with less skin irritation and an excellent action of strongly suppressing scratching behavior, and pharmaceutical compositions containing a quinazoline derivative as an active ingredient. The present invention is directed to the quinazoline derivatives represented by the general formula [1] or pharmaceutically acceptable salts thereof. In the general formula [1], R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 and R4 are the same or different and represent hydrogen, alkyl, alkoxy or halogen; R5 is combined with R6 to represent alkylene or represents hydrogen, hydroxy, alkyl, phenyl or alkoxy; R6 represents alkyl, cycloalkyl, phenyl, a 5- to 10-membered aromatic heterocyclic group containing one to three heteroatoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, or —N(R6-1)(R6-2).
    Type: Application
    Filed: October 3, 2006
    Publication date: January 28, 2010
    Applicant: NIPPON SHINYAKU CO., LTD.
    Inventors: Masahiko Okano, Tatsuya Oyama
  • Publication number: 20100009958
    Abstract: Quinazoline derivatives of the following formula: wherein R1, R2, R3, R4, R5, X, Y, and Z are defined herein. It also discloses a method of treating cancer with one of these compounds.
    Type: Application
    Filed: June 30, 2008
    Publication date: January 14, 2010
    Applicant: Hutchison MediPharma Enterprises Limited
    Inventors: Weihan Zhang, Wei-Guo Su, Haibin Yang, Yumin Cui, Yongxin Ren, Xiaoqiang Yan
  • Publication number: 20100010023
    Abstract: A compound of general formula I wherein: Ra is a benzyl, 1-phenylethyl, or 3-chloro-4-fluorophenyl group; Rb is a dimethylamino, N-methyl-N-ethylamino, diethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, N-methyl-N-(tetra-hydrofuran-3-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino, N-methyl-N-(tetra-hydrofuran-3-ylmethyl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, or N-methyl-N-(tetrahydropyran-4-ylmethyl)amino group; and Rc is a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group, or a tautomer, stereoisomer, or salt thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction
    Type: Application
    Filed: September 21, 2009
    Publication date: January 14, 2010
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Frank HIMMELSBACH, Elke LANGKOPF, Stefan BLECH, Birgit JUNG, Anke BAUM, Flavio SOLCA
  • Publication number: 20090304635
    Abstract: The present invention provides methods of treating baldness in a subject and generating new hair follicles, comprising epidermal disruption and administration of a compound that promotes a differentiation of an uncor?mitted epidermal cell into a hair follicle cell. The present invention also provides methods for hair removal and inducing hair pigmentation.
    Type: Application
    Filed: March 28, 2006
    Publication date: December 10, 2009
    Inventors: George Cotsarelis, Mayumi Ito
  • Publication number: 20090306044
    Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
    Type: Application
    Filed: November 9, 2006
    Publication date: December 10, 2009
    Inventors: Flavio Solca, Andree Amelsberg, Gerd Stehle, Jacobus C.A. Van Meel, Anke Baum
  • Publication number: 20090306101
    Abstract: The invention relates to a therapy of cancer comprising co-administration to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amounts of: (1) a compound 1 of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification; and (2) at least a further chemotherapeutic agent 2; optionally in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery, furthermore, the invention relates to corresponding medicaments and the preparation thereof.
    Type: Application
    Filed: November 9, 2006
    Publication date: December 10, 2009
    Inventors: Flavio Solca, Andree Amelsberg, Gerd Stehle, Jacobus C.A. Van Meel, Anke Baum
  • Patent number: 7625911
    Abstract: The present invention relates to novel amorphous form of [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl) (erlotinib hydrochloride), to solid amorphous dispersion of erlotinib hydrochloride and a carrier such as PVP or solid PEG, to processes for their preparations, to pharmaceutical compositions containing them and to method of treatment using the same. The amorphous form or solid amorphous dispersion of erlotinib hydrochloride obtained in this invention is useful in preparing pharmaceutical dosage forms.
    Type: Grant
    Filed: January 12, 2005
    Date of Patent: December 1, 2009
    Assignee: Mai De Ltd.
    Inventor: Le Huang
  • Publication number: 20090291950
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PD E4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Application
    Filed: July 6, 2007
    Publication date: November 26, 2009
    Applicant: KALYPSYS, INC.
    Inventors: Steven P. Govek, Andrew K. Shiau, Stewart A. Noble, David J. Thomas
  • Publication number: 20090285782
    Abstract: This invention provides quinazoline derivatives represented by the structural formula: (I); wherein: R2 is hydrogen, NR?R?, C1-7 alkyl, arylC1-7 alkyl or C3-10 cycloalkyl; R4 is amino, C1-7 alkyl, C2-7 alkenyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, aryl, heterocyclic, arylalkyl, heterocyclic-substituted C1-7 alkyl or C3-10 cycloalkyl-C1-7 alkyl; R5 is hydrogen or C1-7 alkyl, or R5 and R4 together with the nitrogen atom to which they are attached form a heterocyclic ring; Y is a single bond, C1-7alkylene, C2-7 alkenylene or C2-7 alkynylene; R6 is halogen, heteroaryl or aryl; R? and R? are each independently hydrogen, C1-7 alkyl-carbonyl or C1-7 alkyl; provided that R4 is not phenyl substituted with morpholino when R2 is H and R5 is H, and provided that when NR4R5 is piperazinyl, said NR4R5 is either non-substituted or substituted with methyl or acetyl; a pharmaceutically acceptable addition salt, a stereoisomer, a mono- or a di-N-oxide, a solvate or a pro-drug thereof, for the treatment of viral infections.
    Type: Application
    Filed: July 20, 2007
    Publication date: November 19, 2009
    Applicant: Gilead Sciences, Inc.
    Inventors: Ling-Jie Gao, Piet André Maurits Maria Herdewijn, Steven Cesar Alfons De Jonghe, William John Watkins, Lee Shun Chong
  • Publication number: 20090286850
    Abstract: The present invention provides methods of identifying an agents that inhibit tumor cells from undergoing an epithelial to mesenchymal transition, impair tumor cell mobility, and thus inhibit tumorigenicity. The present invention also provides compositions comprising said agents, and methods for their preparation and use. The present invention also provides methods for inhibiting tumor cells in a patient from undergoing an epithelial to mesenchymal transition by administration of inhibitors of PAK2 kinase, that optionally also inhibit PAK1 kinase. Such methods may be employed in combination with other anti-cancer agents such as EGFR or IGF-1R kinase inhibitors.
    Type: Application
    Filed: March 6, 2009
    Publication date: November 19, 2009
    Inventors: Salam A. Shaaban, Jonathan A. Pachter
  • Patent number: 7618975
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: July 6, 2004
    Date of Patent: November 17, 2009
    Assignees: Myriad Pharmaceuticals, Inc., Cytovia, Inc.
    Inventors: Sui Xiong Cai, Nilantha Sudath Sirisoma, Azra Pervin, John A. Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman
  • Publication number: 20090281129
    Abstract: The invention relates to the inhibition of the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.
    Type: Application
    Filed: August 7, 2008
    Publication date: November 12, 2009
    Inventors: Bey-Dih Chang, Igor B. Roninson, Donald Porter
  • Publication number: 20090274626
    Abstract: The invention provides methods for modulating tumor cell proliferation by contacting cells (e.g. tumor cells) with a TACE inhibitor and a compound that inhibits EGFR tyrosine kinase, whereby the TACE inhibitor enhances the sensitivity of the cell to the EGFR tyrosine kinase inhibitor. Additionally, methods for treating cancer and methods for identifying TACE inhibitors is also provided.
    Type: Application
    Filed: January 29, 2008
    Publication date: November 5, 2009
    Applicant: The Regents of the University of California
    Inventors: Paraic A. Kenny, Mina J. Bissell
  • Publication number: 20090270397
    Abstract: A method of potentiating the efficacy of an antineoplastic agent such as temozolomide, comprises the administration of an antifolate agent as defined herein. Also disclosed are compositions, including pharmaceutical compositions, comprising the antineoplastic agent and an antifolate agent, and the use of such compounds and compositions thereof to treat a variety of cancers, such as melanoma. Unit dosage forms and kits are also contemplated and disclosed.
    Type: Application
    Filed: April 8, 2009
    Publication date: October 29, 2009
    Inventors: Seth J. Orlow, Ming Chen
  • Publication number: 20090269354
    Abstract: This invention relates to novel quinazoline derivatives, and their pharmaceutically acceptable salts. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by inhibiting cell surface tyrosine receptor kinases.
    Type: Application
    Filed: March 27, 2009
    Publication date: October 29, 2009
    Applicant: Concert Pharmaceuticals, Inc.
    Inventors: Craig E. Masse, Roger Tung
  • Patent number: 7601713
    Abstract: The present disclosure provides compounds that inhibit protein kinases, such as JAK, Axl, or Syk kinases, compositions comprising the compounds and methods of using the compounds to inhibit protein kinase and treat and/or prevent diseases associated with inappropriate kinase activity.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: October 13, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Pingyu Ding, Ankush Argade, Dane Goff, Rajinder Singh, Esteban Masuda, Vanessa Taylor, Sacha Holland
  • Publication number: 20090253719
    Abstract: The present invention provides methods of preparing antifolate compounds. The inventive methods can particularly be use for preparing compounds exhibiting improved bioavailability, making the compound particularly useful in pharmaceutical compositions. The compounds prepared according to the inventive methods are useful in the treatment of multiple conditions, including abnormal cell proliferation, inflammatory diseases, asthma, and arthritis.
    Type: Application
    Filed: April 7, 2009
    Publication date: October 8, 2009
    Inventors: Harish K. Pimplaskar, Mikhail Lebedev, Karol Horvath
  • Publication number: 20090253721
    Abstract: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient a therapeutically effective amount of an EGFR kinase inhibitor, combined with treating the patient simultaneously or sequentially with radiation therapy, with or without additional agents or treatments, such as other anti-cancer drugs. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlitinib HCl (also known as Tarceva™).
    Type: Application
    Filed: June 5, 2009
    Publication date: October 8, 2009
    Inventors: Paul M. HARARI, Prakash CHINNAIYAN, Shyhmin Jason HUANG
  • Publication number: 20090253720
    Abstract: The present invention provides pharmaceutical compositions comprising an antifolate compound. The composition exhibit improved bioavailability, and they particularly incorporate beneficial excipients that increase solubility and bioavailability, such as cyclodextrins or compounds formed of fatty acid esters of glycerol and polyethylene glycol esters. The pharmaceutical compositions are useful in the treatment of multiple conditions, including abnormal cell proliferation, inflammatory diseases, asthma, and arthritis.
    Type: Application
    Filed: April 7, 2009
    Publication date: October 8, 2009
    Inventors: Michael J. Roberts, Harish K. Pimplaskar
  • Publication number: 20090247519
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain amino-ethyl-amino-aryl (AEAA) compounds which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.
    Type: Application
    Filed: April 26, 2007
    Publication date: October 1, 2009
    Inventors: Tony Michael Raynham, Timothy Robin Hammonds, Julia Helen Gilliatt, Mark David Charles, Gregoire Alexandre Pave, Caroline Heather Foxton, James Lindsay Carr, Neela Sumit Mistry
  • Publication number: 20090246196
    Abstract: A method of treating an individual comprising: evaluating the disease state of said individual through quantitative and/or qualitative assays; administering in amounts sufficient to treat said disease at least three agents wherein at least one agent is an inhibitor of the human epidermal receptor pathway, at least one agent is signal transduction inhibitor and at least one agent is an angiogenesis inhibitor and; reevaluating the disease state of said individual presenting through quantitative and/or qualitative assays. A composition comprising a first agent that is an inhibitor of the human epidermal receptor pathway, a second agent that is an angiogenesis inhibitor and a third agent that is an inhibitor of Akt wherein said first agent, second agent, third agent and combinations thereof are present in amounts that when administered to an individual in a diseased state are sufficient to treat said disease.
    Type: Application
    Filed: March 15, 2007
    Publication date: October 1, 2009
    Inventors: Leo Linbeck, III, Martin Lindenberg, John J. Nemunaitis, Neil Senzer, David Shanahan
  • Publication number: 20090233949
    Abstract: The invention relates to the compounds of formula (I) having antithrombotic activity which especially inhibit blood clotting factor IXa, to methods for producing the same and to the use thereof as drugs.
    Type: Application
    Filed: March 9, 2009
    Publication date: September 17, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Henning STEINHAGEN, Markus FOLLMANN, Jochen GOERLITZER, Herman SCHREUDER
  • Publication number: 20090226377
    Abstract: The present invention relates to a quinoline or quinazoline derivative having the general formula (A): in which R3, R4, W, Y and Q are indicated in the description and the claims, the use of the compounds of the general formula (A) for the treatment of various disorders, and the preparation of compounds of the general formula (A).
    Type: Application
    Filed: May 23, 2008
    Publication date: September 10, 2009
    Inventors: Knut EIS, Olaf Prien, Ulrich Lucking, Judith Gunther, Dieter Zopf, Dirk Brohm, Verena Vohringer, Elisabeth Woltering, Hartmut Beck, Mario Lobell, Volkhart Min-Jian Li, Susanne Greschat
  • Publication number: 20090226443
    Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to combination therapies for the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: March 6, 2009
    Publication date: September 10, 2009
    Applicant: Genentech, Inc.
    Inventors: Ellen Filvaroff, Mark Merchant, Robert L. Yauch
  • Publication number: 20090209496
    Abstract: This invention relates to methods for treating, preventing and/or managing cancer in a subject including enhancing the efficacy of a Receptor Tyrosine Kinase inhibitor (e.g., a small molecule RTK inhibitor, e.g., Sorafenib or Erlotinib) by administering to the subject a Vascular Disrupting Agent (e.g., a Combretastatin or derivative thereof) sequentially or simultaneously in combination with said RTK inhibitor. Pharmaceutical compositions comprising a combination of a RTK inhibitor and a VDA are also provided.
    Type: Application
    Filed: February 17, 2009
    Publication date: August 20, 2009
    Inventors: David Chaplin, Bronwyn G. Siim
  • Patent number: 7576074
    Abstract: The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.
    Type: Grant
    Filed: July 14, 2003
    Date of Patent: August 18, 2009
    Inventors: Kenneth D. Rice, Neel K. Anand, Joerg Bussenius, Abigail R. Kennedy, Angie I. Kim, Csaba J. Peto, Tsze H. Tsang
  • Publication number: 20090203718
    Abstract: The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and an IGF-1R inhibitor to a mammal suffering from a cancer.
    Type: Application
    Filed: April 13, 2006
    Publication date: August 13, 2009
    Applicant: SmithKline Beecham (Cork) Ltd.
    Inventors: David Rusnak, Tona Morgan Gilmer
  • Publication number: 20090186892
    Abstract: The present invention provided methods for treating lung cancers using therapeutic agents for lung cancers comprising erbB receptor inhibitors as active ingredients. Methods for examining the responsiveness of lung cancer patients to erbB receptor inhibitors by using blood amphiregulin (AREG) as an indicator were provided. Furthermore, methods for treating lung cancers in which responsiveness to an erbB receptor inhibitor is determined based on blood AREG concentration, and in which therapeutic agents are selectively administered to patients expected to be responsive, were also provided. Advanced therapeutic effects can be expected by administering an erbB receptor inhibitor to patients predicted to be responsive. The present invention contributes to the improvement of therapeutic effects of gefitinib (Product name: Iressa®) and such on lung cancers.
    Type: Application
    Filed: February 10, 2006
    Publication date: July 23, 2009
    Applicant: Oncotherapy Science, Inc
    Inventors: Yusuke Nakamura, Yataro Daigo
  • Publication number: 20090186911
    Abstract: The present invention relates to sulphoximine-substituted quinazoline derivatives of the formula (I), processes for their preparation and their use as a medicament for the treatment of various diseases.
    Type: Application
    Filed: June 13, 2008
    Publication date: July 23, 2009
    Inventors: Duy NGUYEN, Arne von Bonin, Michael Haerter, Hartmut Schirok, Anne Mengel, Martina Schaefer, Oliver von Ahsen
  • Publication number: 20090175869
    Abstract: This invention relates to pulsatile dose administration of gossypol, a gossypol-related compound or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol or gossypol-related compound, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis.
    Type: Application
    Filed: December 10, 2008
    Publication date: July 9, 2009
    Applicant: Ascenta Therapeutics, Inc.
    Inventors: Jon T. Holmlund, Mel Sorensen, Lance Leopold, Dajun Yang
  • Publication number: 20090175856
    Abstract: The present invention describes a method or uses of prevention and/or treatment of a cancer or a tumor, and in particular to a combination therapy, methods, compositions and pharmaceutical packages comprising an inhibitor of receptors of the EGFR family or a chemotherapeutically active pyrimidine analogue and certain platinum-based chemotherapeutic agents.
    Type: Application
    Filed: November 13, 2006
    Publication date: July 9, 2009
    Inventors: Katja Wosikowski-Buters, Christoph Schaab, Marino Schuhmacher, Franz Obermayr, Igor Ivanov
  • Publication number: 20090170880
    Abstract: Provided are Breast Cancer Resistance Protein (BCRP) inhibitors, P-glycoprotein (P-gp) inhibitors and chemotherapeutic agents for use in the treatment of cancer by combination therapy of the BCRP inhibitor and/or P-gp inhibitor with the chemotherapeutic agent. The chemotherapeutic agent is an imidazotetrazine, e.g. temozolomide.
    Type: Application
    Filed: August 7, 2008
    Publication date: July 2, 2009
    Inventor: Olaf Van Tellingen
  • Publication number: 20090155247
    Abstract: Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and EGFR inhibitors to treat pathological conditions such as cancer are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies in combination with EGFR inhibitors, such as Tarceva™.
    Type: Application
    Filed: February 16, 2006
    Publication date: June 18, 2009
    Inventor: Avi J. Ashkenazi
  • Patent number: 7547702
    Abstract: Quinazolines of the formula (I) in which R, R1, R2, R3, R4 and Y have the meaning indicated in Patent claim 1, and their salts or solvates as glycoprotein 1bIX antagonists.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: June 16, 2009
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Werner Mederski, Maria Devant, legal representative, Gerhard Barnickel, Sabine Bernotat-Danielowski, James Vickers, Bertram Cezanne, Daljit Dhanoa, Bao-Ping Zhao, James Rinker, Mark R. Player, Edward Jaegar, Richard Soll, Ralf Devant
  • Publication number: 20090148494
    Abstract: Compositions and methods for promoting neural regeneration in a patient determined to have a lesion in a mature CNS neuron are disclosed. The method comprises the step of contacting the neuron with an EGFR inhibitor sufficient to promote regeneration of the neuron.
    Type: Application
    Filed: February 18, 2009
    Publication date: June 11, 2009
    Inventors: Zhigang He, Vuk Koprivica
  • Patent number: 7544691
    Abstract: The invention relates to the guanine derivatives of general formula (I), and to hydrates or solvents thereof, for use as neuropeptide FF receptor antagonists in the treatment of pains and hyperalgesia, of withdrawal symptoms of addiction to alcohol, psychotropic drugs or nicotine and in the prevention of or recovery from these addictions, for the regulation of insulin release, food intake, memory functions, blood pressure, electrolyte and energy metabolism, and in the treatment of urinary incontinence
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: June 9, 2009
    Assignee: Actelion Pharmaceuticals, Ltd.
    Inventors: Volker Breu, Anja Fecher, Heinz Fretz, Thomas Giller, Kurt Hilpert, Olivier Valdenaire
  • Publication number: 20090136517
    Abstract: The present invention provides a composition and a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and a KIT kinase inhibitors, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as TARCEVA®). A preferred example of a KIT kinase inhibitor that can be used in practicing this invention is OSI-930 and OSI-817.
    Type: Application
    Filed: November 26, 2008
    Publication date: May 28, 2009
    Inventors: Andrew J. Garton, Maryland Franklin
  • Publication number: 20090137567
    Abstract: Methods of treating blood disorders are described.
    Type: Application
    Filed: September 17, 2008
    Publication date: May 28, 2009
    Applicant: HEMAQUEST PHARMACEUTICALS, INC.
    Inventors: Susan P. Perrine, Regine Bojacek
  • Publication number: 20090137583
    Abstract: The present invention provides 2-aminoquinazoline derivatives represented by formula (I): wherein R1 and R2 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, and the like; X represents a bond or CR7aR7b wherein R7a and R7b may be the same or different and each represents a hydrogen atom, and the like; when X is a bond, R3 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; when X is CR7aR7b wherein R7a and R7b have the same meanings as defined above, respectively, R3 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted aryl, and the like; R4 represents a hydrogen atom, hydroxy, substituted or unsubstituted lower alkoxy, and the like; and R5 represents a hydrogen atom, substituted or unsubstituted aryl, and the like, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 28, 2006
    Publication date: May 28, 2009
    Applicant: KYOWA HAKKO KOGYO CO., LTD.
    Inventors: Kuniyuki Kishikawa, Hidetomo Imase, Hajime Kashima, Kiyotoshi Mori, Toshihide Ikemura, Yoshisuke Nakasato, Misato Tomuro
  • Publication number: 20090124642
    Abstract: The invention provides a novel crystalline form of Erlotinib HCl, processes for its preparation, and formulations thereof.
    Type: Application
    Filed: August 25, 2008
    Publication date: May 14, 2009
    Inventors: Augusto Canavesi, Marco Villa, Ales Gavenda, Jiri Faustmann, Judith Aronhime, Ettore Gibatti, Alexandr Jegorov
  • Publication number: 20090118311
    Abstract: Compounds of formula (I) or (II) are dihydrofolate reductase inhibitors, useful for the treatment of, for example, cell proliferative diseases: wherein A and D are independently —CHR7— or —NR7—; E and G are independently ?CR7— or ?N—; each R6 independently represents hydrogen or —OR7; R7 is hydrogen or C1-C6 alkyl; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid which does not contain a carboxyl, or carboxyl ester group; Y is a bond, —C(?O)—, —S(?O)2—, —C(?O)NR3—, —C(?S)—NR3, —C(?NH)NR3 or —S(?O)2NR3— wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n and p are independently 0 or 1, and Q, Alk1 and Alk2 are as defined in the claims; X1 represents a bond; —C(?O); or —S(?O)2—; —NR4C(?O)—, —C(?O)NR4—, —NR4C(?O)NR5—, —NR4S(?O)2—, or —S(?O)2NR4— wherein R
    Type: Application
    Filed: April 24, 2007
    Publication date: May 7, 2009
    Inventor: Alan Hornsby Davidson
  • Publication number: 20090105166
    Abstract: The present invention provides novel tricyclic spiro-oxathiine naphthoquinone derivatives, a synthetic method for making the derivatives, and the use of the derivatives to induce cell death and/or to inhibit proliferation of cancer or precancerous cells. The naphthoquinone derivatives of the present invention are related to the compound known as ?-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione).
    Type: Application
    Filed: August 21, 2007
    Publication date: April 23, 2009
    Inventors: Mark A. Ashwell, Manish Tandon, Jean-Marc Lapierre, Syed Ali, David Vensel, Chiang J. Li
  • Publication number: 20090105211
    Abstract: The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.
    Type: Application
    Filed: March 14, 2008
    Publication date: April 23, 2009
    Applicant: Exelixis, Inc.
    Inventors: Suleyman Bahceci, William Bajjalieh, Jeff Chen, Sergey Epshteyn, Timothy Patrick Forsyth, Tai Phat Huynh, Byung Gyu Kim, James W. Leahy, Matthew Sangyup Lee, Gary L. Lewis, Morrison B. Mac, Grace Mann, Charles K. Marlowe, Brian Hugh Ridgway, Joan C. Sangalang, Xian Shi, Craig Stacy Takeuchi, Yong Wang
  • Patent number: 7521456
    Abstract: The present invention relates to the anhydrous and hydrate forms of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate. The invention also relates to pharmaceutical compositions containing N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and to methods of treating hyperproliferative disorders, such as cancer, by administering N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: April 21, 2009
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Douglas John Meldrum Allen, Timothy Norris, Jeffrey William Raggon, Dinos Paul Santafianos, Ravi Mysore Shanker
  • Publication number: 20090087441
    Abstract: Novel wortmannin analogs and their use in inhibiting PI-3-kinase activity in mammals and the treatment or prevention of cancer and tumor formation in a subject are described herein. Preferably, the wortmannin analogs may be administered with other chemotherapeutic agents in the treatment of cancer.
    Type: Application
    Filed: September 23, 2008
    Publication date: April 2, 2009
    Applicants: Prolx Pharmaceuticals Corp., Arizona Board of Regents, acting on hehalf of The University of Arizona, The University of Pittsburgh
    Inventors: Lynn Kirkpatrick, Garth Powis, Peter Wipf
  • Publication number: 20090082371
    Abstract: A method using quinazoline derivatives, celastrol, cape, BAY 11-7082, rocaglamide, and 7-Methoxy-5,11,12-trihydroxy-coumestan is administered to a mammal for the treatment and prevention of viral diseases and cancers. The chemical compounds are targeted to inhibit NF-?B transcriptional activity. These treatments for viral diseases, especially for infection caused by HIV, and cancers may be accomplished utilizing quinazoline derivatives, celastrol, cape, BAY 11-7082, rocaglamide, 7-Methoxy-5,11,12-trihydroxy-coumestan, and compounds similar to them alone or in combination with prior art other therapy.
    Type: Application
    Filed: June 19, 2006
    Publication date: March 26, 2009
    Inventor: Zhimin Lu